Nature Medicine· Justin Budka·· 28 天前精选AI 评分71
多中心多试验队列分析:淋巴瘤患者CAR T细胞疗法反应的决定因素
Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma
AI 导读
研究发现,CAR T细胞疗法前输注产品中具有幼稚样和干细胞记忆样CCR7+CD45RA+ T细胞的比例较高,与更好的临床疗效和更持久的益处相关。
推荐理由
分析了多个临床试验的样本,揭示了CAR T细胞疗法疗效的潜在生物标志物。
正文 · 原文
Nature Medicine, Published online: 23 October 2026; doi:10.1038/s41591-026-04707-w
A large comprehensive analysis of clinical trial samples from patients with non-Hodgkin lymphoma who were treated with anti-CD19 CAR T therapy shows that a high proportion of naive-like and stem cell memory-like CCR7+CD45RA+ T cells in the pre-infusion CAR T product correlates with improved and prolonged clinical benefit, which was validated in an independent external cohort including different products.
来源:Nature Medicine · nature.com